Bryn Mawr Capital Management LLC Cuts Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Bryn Mawr Capital Management LLC cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 48.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,089 shares of the medical instruments supplier’s stock after selling 4,756 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $1,241,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of BDX. OFI Invest Asset Management purchased a new stake in Becton, Dickinson and Company during the third quarter worth about $25,000. Fortitude Family Office LLC purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $35,000. Venturi Wealth Management LLC increased its stake in shares of Becton, Dickinson and Company by 552.0% during the fourth quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 138 shares during the period. Arlington Trust Co LLC purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $41,000. Finally, MCF Advisors LLC increased its stake in shares of Becton, Dickinson and Company by 51.4% during the fourth quarter. MCF Advisors LLC now owns 212 shares of the medical instruments supplier’s stock worth $52,000 after buying an additional 72 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX stock opened at $231.55 on Friday. The company has a market capitalization of $66.89 billion, a P/E ratio of 54.87, a PEG ratio of 1.90 and a beta of 0.43. Becton, Dickinson and Company has a twelve month low of $229.40 and a twelve month high of $287.32. The business has a 50 day simple moving average of $239.24 and a 200-day simple moving average of $241.42. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. During the same period last year, the company earned $2.98 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Raymond James increased their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Barclays increased their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.